A Limited Food Effect Study of Gabapentin 800 mg Tablets
Status:
Completed
Trial end date:
1999-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin
Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by
Parke-Davis following a single oral dose (1 x 800 mg tablet) or (2 x 400 mg capsules) in
healthy adult male volunteers under non-fasting conditions, and will compare the differences
in plasma levels after dosing the test formulation with and without food.